Spurr Robert
Known title: U.S. President-Pharma BusinessCIK: 0001543795
Associated companies
Transaction History
| BHC | ▲ Buy | Option Exercise | 8,643 | — | 5/10/2022 | View on chart |
| BHC | ▲ Buy | Option Exercise | 13,592 | — | 5/10/2022 | View on chart |
| BHC | ▼ Sell | Open Market | 1,595 | $35K | 4/14/2022 | View on chart |
| BHC | ▼ Sell | Open Market | 4,846 | $108K | 3/15/2022 | View on chart |
| BHC | ▼ Sell | Tax Withholding | 4,074 | $96K | 3/3/2022 | View on chart |
| BHC | ▼ Sell | Open Market | 1,595 | $37K | 3/2/2022 | View on chart |
| BHC | ▲ Buy | Grant | 35,627 | $861K | 3/2/2022 | View on chart |
| BHC | ▲ Buy | Option Exercise | 15,615 | — | 2/27/2022 | View on chart |
| BHC | ▼ Sell | Tax Withholding | 5,646 | $137K | 2/27/2022 | View on chart |
| BHC | ▼ Sell | Tax Withholding | 1,651 | $40K | 2/27/2022 | View on chart |
| BHC | ▼ Sell | Tax Withholding | 1,628 | $40K | 2/26/2022 | View on chart |
| BHC | ▼ Sell | Open Market | 3,251 | $81K | 2/15/2022 | View on chart |
| BHC | ▼ Sell | Open Market | 3,251 | $87K | 1/18/2022 | View on chart |
| BHC | ▼ Sell | Tax Withholding | 283 | $8K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance
Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.